Register for In-Person
(On Site) Attendance     Register for Remote
(Virtual) Attendance

August 21 - 23, 2025
Mission Bay Conference Center • San Francisco, CA
Course# MDM26F01 - Department: Medicine

Overview

The Rheumatology Board Review and Clinical Update course has been offered by UCSF since 1992 and will be presented as a hybrid conference - in person and virtually this year. Join us for three days of a live and live-streamed interactive conference which will include talks on major clinical topics in Rheumatology to assist physicians preparing for the American Board of Internal Medicine (ABIM) Subspecialty Examination in Rheumatology. The course will provide up to date information for practicing clinicians seeking to improve their care for rheumatology patients. An additional series of prerecorded lectures and practice questions are also available to participants.

Target Audience
Trainees preparing for their initial board exam — as well as rheumatologists who are candidates for ABIM recertification — are the target audience. Diagnosing and managing complex and unusual clinical problems will be emphasized; an overview of significant advances related to clinical rheumatology will also be included.

Onsite and Remote Learning Options:
The course sessions will take place at the Mission Bay Conference Center.  Live Stream and Onsite registrants will receive instructions along with the digital syllabus a week before the conference.  Included in your registration fee is access to the course recordings on demand after the conference for a limited time period. You must tune in to live conference (in person or remotely) to claim CME.  All course times listed are Pacific Standard Time.

Objectives

An attendee completing this course should be able to:

1. Apply current, evidence-based standards of care to rheumatic diseases (including rheumatoid arthritis, systemic lupus erythematosus, scleroderma, other systemic, autoimmune diseases, autoinflammatory diseases, spondyloarthritis, osteoarthritis, osteoporosis, crystalline arthritis, and soft tissue musculoskeletal pain syndromes);
2. Improve diagnostic accuracy by application of best available recent data and expert guidance.
3. Refine, optimize, and monitor rheumatic disease treatments based on new knowledge of efficacy and safety.
4. Adopt newly approved treatments appropriately based on the latest medical evidence.
5. Refine approach to pain in rheumatic diseases.
6. Increase utilization of self-assessment.